二至丸活性成分及多靶点作用机制缓解代谢功能障碍相关脂肪性肝炎
本研究采用MCD饮食(非肥胖型)和HFHC饮食(肥胖型)两种MASH小鼠模型,结合多组学、UPLC-Q-Exactive-Orbitrap-MS分析和分子对接,发现二至丸可减轻肝脏脂质堆积、胰岛素抵抗、炎症、凋亡和纤维化。其机制涉及激活PPARα和PI3K/AKT/FoxO1通路,抑制NLRP3、p53和YAP信号通路;主要活性成分为蟛蜞菊内酯、特女贞苷、红景天苷和刺囊酸-3-O-葡萄糖苷,其中红景天苷与刺囊酸-3-O-葡萄糖苷联用抗MASH效果与二至丸相当。
要点
- 二至丸在MCD和HFHC饮食诱导的MASH小鼠中均能减轻肝脂质堆积、炎症、凋亡和纤维化。
- 二至丸通过激活PPARα和PI3K/AKT/FoxO1、抑制NLRP3/p53/YAP通路发挥多靶点治疗作用。
- 红景天苷与刺囊酸-3-O-葡萄糖苷是二至丸抗MASH的主要活性成分,联用效果与二至丸相当。
核心结论
- 二至丸及其活性成分组合(红景天苷与刺囊酸-3-O-葡萄糖苷)是多靶点治疗MASH的潜在方案。
研究设计与样本
- 研究使用MCD饮食诱导的非肥胖型MASH小鼠和HFHC饮食诱导的肥胖型MASH小鼠两种体内模型。
- 体外采用FFA刺激的HepG2细胞和TGF-β1激活的LX-2细胞探究活性成分的作用及机制。
主要发现
- 二至丸减轻不同饮食诱导MASH小鼠的肝脏脂质堆积、胰岛素抵抗、炎症、凋亡和纤维化。
- 二至丸激活PPARα和PI3K/AKT/FoxO1通路,抑制NLRP3、p53和YAP信号通路。
- 蟛蜞菊内酯、特女贞苷、红景天苷和刺囊酸-3-O-葡萄糖苷被鉴定为二至丸抗MASH的主要活性成分。
- 体外实验证实特女贞苷、红景天苷和刺囊酸-3-O-葡萄糖苷通过激活PPARα减轻脂质积累。
- 特女贞苷和红景天苷通过激活PI3K/AKT/FoxO1通路改善胰岛素抵抗。
关键数值与推荐
- 二至丸在MCD饮食和HFHC饮食诱导的MASH小鼠中均表现出治疗作用。
- 红景天苷与刺囊酸-3-O-葡萄糖苷联合的抗MASH疗效与二至丸相当。
临床怎么用
- 二至丸可作为MASH的潜在治疗选择,尤其适用于多靶点干预需求的患者。
- 红景天苷与刺囊酸-3-O-葡萄糖苷的组合可能作为二至丸的简化替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Erzhi pills (EZP), as a traditional Chinese herbal prescription, have protective effects against various forms of liver injury. However, the therapeutic potential, bioactive ingredients and mechanism of action of EZP for metabolic dysfunction-associated steatohepatitis (MASH) have not been completely elucidated. AIM OF THE STUDY: This research aimed to evaluate the therapeutic effect of EZP and its bioactive compounds on MASH. METHODS: Two typical animal models of MASH, mice fed a methionine-choline-deficient (MCD) diet (representing non-obese MASH) and mice fed a high-fat and high-cholesterol diet (HFHC) (representing obese MASH), were used to investigate the effect of EZP on MASH in vivo. Transcriptomic and proteomic analysis were performed to elucidate the under lying mechanisms of EZP. The compositional analysis of EZP in MASH mice was conducted using UPLC-Q-Exactive-Orbitrap-MS. Free fatty acid (FFA)-stimulated HepG2 cells and transforming growth factor β1 (TGF-β1)-activated LX-2 cells were applied to further explore the effects and mechanisms of bioactive compounds from EZP. RESULTS: Our results indicate that the EZP mitigates hepatic lipid buildup, insulin resistance, inflammation, apoptosis, and fibrosis in different diet-induced MASH mice. Through multiomic analyses, UPLC-Q-Exactive-Orbitrap-MS analysis and molecular docking, we have identified that EZP exerts therapeutic effects on MASH involves activation of PPARα and PI3K/AKT/FoxO1 pathways, and inhibition of NLRP3, p53, and yes-associated protein (YAP) signaling pathways. It had been established that wedelolactone (wed), specnuezhenide (Spe), salidroside (Sal), and echinocystic acid-3-o-glucoside (Ech) served as the primary bioactive compounds in EZP for its therapeutic effect against MASH. In vitro experiments have confirmed that Spe, Sal, and Ech mitigate lipid accumulation by activating PPARα. Additionally, Spe and Sal improve insulin resistance through the activation of the PI3K/AKT/FoxO1 signaling pathway. Furthermore, Wed, Sal, and Ech inhibit the NLRP3 inflammasome and p53 signaling pathways, thereby reducing inflammatory markers and providing anti-apoptotic effects. Moreover, Wed and Ech inhibit the activation of hepatic stellate cells (HSCs) by blocking the YAP signaling pathway. Notably, Sal and Ech were the primary bioactive components of EZP, and their combined anti-MASH efficacy was comparable to that of EZP. CONCLUSION: This study is the comprehensive elucidation of the active ingredients and mechanism of action behind EZP in its anti-MASH properties. EZP, as well as the combination of Sal and Ech are potential treatment for MASH that targets multiple signaling pathways.
引用
- Gao K, Zhang W, Zhao M, et al. Bioactive compounds and multitarget action mechanism of Erzhi pills in alleviating metabolic dysfunction-associated steatohepatitis. J Ethnopharmacol. 2025. PMID: 41093119. doi:10.1016/j.jep.2025.120737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。